The 2025 Joint Congress of the American Academy of Allergy, Asthma & Immunology (AAAAI) and the World Allergy Organization (WAO) was held February 28 to March 3 in San Diego, California.

Attendees from around the globe included allergists, immunologists, allied health professionals and others with a special interest in allergic and immunologic diseases.

APFED attended the meeting to offer clinicians educational materials and resources to help their patients learn about and manage eosinophil-associated disease. In the poster hall, we presented one of two research posters highlighting findings on our joint Life with EoE report in collaboration with the Asthma and Allergy Foundation of America (see the Research Abstracts/Posters of Interest below for details) and we participated in a number of discussions to help inform and shape advocacy initiatives, including access to therapies and strategies for continued federal outreach to encourage the full funding of medical research.

Below are some highlights from the meeting. Click or tap on each title to expand that section.

Sessions of Interest

Several sessions specific to eosinophil-associated disease were offered as part of the 2025 Joint Congress as well as industry-sponsored programming. Some of the highlights include:

• Addressing eosinophilic inflammation
• Pediatric hypereosinophilic syndrome
• Strategies for EPGA treatment
• Eosinophilic gastrointestinal disease: year in review
• Optimizing transition of care for eosinophilic gastrointestinal disease from pediatric to adult
• Functional lumen imaging probe in EoE
• Esophageal vs non-esophageal eosinophilic gastrointestinal diseases: similarities and differences
• Triggers and drivers of severe asthma, severe and difficult-to-control asthma and biologics in pediatric asthma

The International Eosinophil Society (IES) hosted a session titled “Emerging Classes of Eosinophil-Directed Precision Therapy: Current and Future Usage and Development.” This session focused on the latest advancements in precision therapies targeting eosinophils, discussing both current applications and future developments in the field.

Research of Interest

A number of research studies were presented at the meeting, both orally and in the poster hall. A few of the highlights are below. To browse all abstracts, visit https://www.jacionline.org/programs_abstracts.

Life with EoE Research

Two posters at the 2025 Joint Congress showcased results of a study conducted in collaboration with APFED and Asthma and Allergy Foundation of America (AAFA) to better understand the patient journey and current state of EoE care in the United States. The project involved surveys and interviews with patients and caregivers and a survey of healthcare providers from various disciplines of medicine.

1. Poster 1: Treatment Adherence in Eosinophilic Esophagitis (EoE): Patient, caregiver, and clinician perspectives. Survey responses from allergists and immunologists highlights the critical role of collaboration with gastroenterologists in treating EoE. However, patient adherence remains a major challenge, with 76% of clinicians citing it as a key issue. While 87% report strong adherence to pharmacological treatments, only 40% see the same for diet therapy. Additionally, 64% of patients and caregivers find diet management difficult, emphasizing the need for multidisciplinary care and strategies to improve adherence. Learn more.

Hannah Jaffee, Mary Jo Strobel, Joy Chang, MD, Mark Holbreich, MD, Jonathan Medernach, MD, Sanaz Eftekhari, Matthew Greenhawt, MD

2. Poster 2: Seeking Care for Eosinophilic Esophagitis (EoE): Patients see multiple providers for EoE. Multidisciplinary care is common in EoE management, yet gaps remain—only 62% of patients see an allergist, and just 15% visit a dietitian. With diet playing a key role in treatment and EoE’s psychosocial impact, enhancing care models among specialists could improve outcomes and reduce redundancy. Learn more.

Hannah Jaffee, Mary Jo Strobel, Joy Chang, MD, Mark Holbreich, MD, Jonathan Medernach, MD, Sanaz Eftekhari, Matthew Greenhawt, MD

Dupilumab Efficacy in Adolescents and Adults with Eosinophilic Esophagitis With and Without Concurrent Elimination Diet: Post Hoc Analysis of LIBERTY EoE TREET at 52 Weeks

A study found that adolescents and adults with eosinophilic esophagitis (EoE) experienced significant improvements when treated with dupilumab, regardless of adherence to food elimination diets. The absolute mean changes in Dysphagia Symptom Questionnaire scores were comparable between those practicing food elimination and those who were not. This suggests that dupilumab’s efficacy in treating EoE is independent of dietary modifications. Learn more.

Antonella Cianferoni, Kathryn Peterson, Eric Low, Changming Xia, PhD, Tiffany Pela, Bram Raphael, Juby Jacob-Nara, Amr Radwa, MD, MB BChir

Baseline Characteristics Associated with Multicomponent Clinical Remission Following Dupilumab Treatment in Patients with Moderate-to-Severe Asthma

A post hoc analysis of the 52-week phase 3 LIBERTY ASTHMA QUEST study assessed 1,530 patients with moderate to severe asthma to determine if baseline characteristics influenced clinical remission with dupilumab. The analysis revealed that higher baseline blood eosinophil counts and elevated fractional exhaled nitric oxide (FeNO) levels were associated with increased odds of achieving clinical remission. Learn more.

Giorgio Canonica, Luis Pérez de Llano, Ian Pavord, Simon Couillard, Celeste Porsbjerg, Guy Brusselle, Mario Castro, MD, MPH, Anju Peters, MD, MSCI, FAAAAI, Arnaud Bourdin, MD, Arman Altincatal, Jason Kwah, Olivier Ledanois

High Incidence and Prevalence of Eosinophilic Esophagitis in the USA Identified: An Analysis of US Health Insurance Claims Data

A recent retrospective study indicates that the incidence and prevalence of eosinophilic esophagitis (EoE) in the United States have risen more than previously estimated. The study found that EoE is more common among individuals aged 18 to 64 compared to those younger or older. These findings underscore the growing need for effective management strategies for EoE across diverse age groups. Learn more.

Matthew Greenhawt, MD MBA MSc FAAAAI, Priya Bansal, MD, FAAAAI, Bridgett Goodwin, Siddhi Korgaonkar, PhD, Yiyan Liu, PhD, Juliana Meyers, MA, Carolyn Schaeffer-Koziol, Eric Shah, MD, MBA, Brian Terreri, PharmD, Evan Dellon, MD

Mepolizumab Reduces Need for Repeat Sinus Surgeries in Patients with Chronic Rhinosinusitis with Nasal Polyps

In Phase III of the SYNAPSE trial researchers found that mepolizumab significantly reduces the risk of repeat sinus surgery in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Read related press release.

Effect Of Randomized Treatment Withdrawal of Budesonide Oral Suspension On The Durability of Dysphagia Symptom Improvement In Patients With Eosinophilic Esophagitis: A Post Hoc Analysis of A Phase 3, 36-Week Trial

Researchers looked at how stopping budesonide oral suspension (BOS) treatment might affect how long the improvement in swallowing difficulties lasts for people with eosinophilic esophagitis. Of the 48 people studied, 25% maintained dysphagia symptom improvement. An average of 8.4 weeks was observed between BOS withdrawal and dysphagia symptom relapse. This suggests that for some patients, symptom improvements following 12 weeks of BOS therapy can be maintained after treatment is stopped. Link to research.

Priya Bansal, MD, Evan Dellon, MD, David Katzka, MD, Gary Falk, MD, Vincent Mukkada, MD, Brian Terreri, PharmD, Carolyn Schaeffer-Koziol, Jessamyn Blau, Cristian Gugiu, Bridgett Goodwin, Muna Tahir

Two-Year Efficacy and Safety of Benralizumab for the Treatment of Eosinophilic Granulomatosis with Polyangiitis

In this study, patients who completed the 52-week double-blind period of the MANDARA trial were invited to enter the open label extension during which they continued benralizumab or switched from mepolizumab to benralizumab. In this study, the patients with EGPA receiving benralizumab, had sustained improvements over two years regarding remission rates, oral glucocorticoids discontinuation, and baseline eosinophil depletion, with low relapse rates. Read the full abstract.

Michael Wechsler, MD, Parameswaran Nair, Nader Khalidi, Benjamin Terrier, Bernhard Hellmich, Arnaud Bourdin, David Jayne, David Jackson, Florence Roufosse, Christian Pagnoux, Ulrich Specks, Lena Börjesson Sjö, Calvin Ho, Maria Jison, Christopher McCrae, Sofia Necander, Eva Rodríguez-Suarez, Anat Shavit, Claire Walton, Peter Merkel.

Exhibit Hall

APFED hosted a booth in the conference’s Exhibit Hall to provide healthcare providers with free print and digital resources to help their patients better understand and manage eosinophil-associated disease. Our booth saw great engagement, with attendees expressing their gratitude for the important work we do.

We’re excited for next year’s AAAAI Annual Meeting in Philadelphia, Pennsylvania! We anticipate the 2026 AAAAI meeting will include a day-long symposium featuring research updates from CEGIR/TIGERs.

When faced with a diagnosis of an eosinophil-associated disease, such as eosinophilic asthma, Eosinophilic Granulomatosis with Polyangiitis (EGPA), or Hypereosinophilic Syndrome (HES), or another subset, you may have questions and concerns.

Eosinophil-associated disease are complex conditions, and making decisions about your treatment can feel overwhelming. One way to ensure that you’re receiving the best care possible is to seek a second opinion.

Why Consider a Second Opinion?

1. Confirming the Diagnosis

Eosinophil-associated diseases are often rare and can sometimes be challenging to diagnose correctly. The symptoms of these conditions can overlap with other illnesses, leading to potential misdiagnosis or delayed treatment. Seeking a second opinion allows another specialist to review your medical history, symptoms, and test results, which can either confirm your original diagnosis or provide new insights that may lead to a different treatment plan.

2. Exploring Treatment Options

There are multiple treatment approaches for eosinophil-associated diseases, and what works for one person may not work for another. A second opinion can introduce you to alternative therapies or new clinical trials that you might not have been aware of. This is especially important if your current treatment isn’t providing relief, if you are experiencing worsening symptoms, or if you’re experiencing side effects that are hard to manage.

3. Accessing Specialized Expertise

Eosinophil-associated diseases are often best managed by specialists who have experience with these specific conditions. If your initial diagnosis was made by a general practitioner or a non-specialist, a second opinion from a gastroenterologist, allergist, immunologist, rheumatologist, or pulmonologist who specializes in these diseases can provide you with a better understanding of your condition.

How to Seek a Second Opinion

1. Talk to Your Current Doctor

Start by discussing your desire for a second opinion with your current doctor. Most doctors will understand and support your decision. They can often recommend another specialist and provide the necessary medical records.

2. Find a Specialist

Look for a doctor who specializes in eosinophil-associated diseases. This might involve researching medical centers known for their work in with eosinophil-associated disease.  You might also look at teaching hospitals or a clinic affiliated with a university, as these institutions often have specialists with the latest knowledge and access to cutting-edge treatments. Specialists can also be found through medical societies (examples include but aren’t limited to the American College of Gastroenterology, or the American Academy of Allergy, Asthma & Immunology. The American Partnership for Eosinophilic Disorders also offers a Specialist Finder.

3. Prepare Your Medical Records

Gather all relevant medical records, including test results, imaging studies, and a list of current medications. Your current doctor can tell you if these records are already digitally accessible to other doctors, or how you can request them from their office. Having these documents ready will help the second doctor provide an informed opinion.

4. Ask the Right Questions

During your second opinion consultation, ask specific questions about your diagnosis, the proposed treatment plan, and any alternatives. For example:

• “Do you agree with the initial diagnosis?”
• “Are there clinical guidelines available for my condition?”
• “What other treatment options are available?”
• “What are the potential side effects of the proposed treatment?”
• “Are there any clinical trials or new therapies I should consider?”

5. Evaluate the Information

After receiving the second opinion, take time to evaluate the information. Compare the recommendations with your current treatment plan and consider your comfort level with the proposed options. It’s important that you feel confident in your care decisions.

This blog post is a research roundup of recent publications on eosinophilic diseases, including summaries, links, and citations for the following articles:

Immune System Reaction to Milk Proteins in Eosinophilic Esophagitis

A multi-institutional study led by researcher David A. Hill, MD, PhD, of Children’s Hospital of Philadelphia (CHOP), identified one of the allergens responsible for eosinophilic esophagitis (EoE) at a molecular level. The preliminary findings, published as a Correspondence Letter to The Journal of Allergy and Clinical Immunology, mark the first time researchers describe molecular details of how the immune system is recognizing food antigens in EoE. Based on this understanding of the milk allergen, the method could be replicated to identify other allergens that result in EoE. This work was supported by APFED donors through our HOPE Pilot Grant Award.

Julianna Dilollo, Alex Hu, Huiqi Qu, Karina E Canziani, Rachel L Clement, Sam J McCright, Wayne G Shreffler, Hakon Hakonarson, Jonathan M Spergel, Karen Cerosaletti, David A Hill. “A molecular basis for milk allergen immune recognition in eosinophilic esophagitis.” The Journal of Allergy and Clinical Immunology. Online January 31, 2025. DOI: 10.1016/j.jaci.2025.01.008.

Six-Month Asthma Control Score on Mepolizumab Predicts Remission in Eosinophilic Asthma

According to data published in The Journal of Allergy and Clinical Immunology: In Practice, among those with severe eosinophilic asthma who are treated with mepolizumab, a patient’s asthma control score at six-months while on this treatment is considered the “best predictor” of whether they will achieve remission in the 12 months that follow. “These results can be used to design a treat-to-target paradigm for asthma, in which treatment response is assessed at 6 months to predict clinical remission,” the study authors concluded.  View the abstract and visual summary.

Yuto Hamada, Peter G Gibso, Erin S Harvey, Sean Stevens, Hayley Lewthwaite, Michael Fricker, Vanessa M McDonald, Andrew Gillman, Mark Hew, Vicky Kritikos, John W Upham, Dennis Thomas. Early Treatment Response to Mepolizumab Predicts Clinical Remission in Severe Eosinophilic Asthma. The Journal of Allergy and Clinical Immunology: In Practice, Volume 13, Issue 2, 333 - 342.e9

Exploring the Underlying Causes of Symptom Severity in Eosinophilic Esophagitis

The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) investigated the underlying causes of symptom severity in eosinophilic esophagitis (EoE) by analyzing gene expression in the esophagus. Findings suggest that the severity of symptoms in EoE may be related to changes in certain cells deep within the esophagus, not just the surface layer. This means that cells beneath the lining of the esophagus might play an important role in how EoE develops and how severe a person’s EoE symptoms become.

• View the abstract and figures from the article published in The Journal of Allergy and Clinical Immunology: In Practice.
• Read a blog post summarizing the study in the Rare Research Report by the Rare Diseases Clinical Research Network (RDCRN).
• Listen to an audio version of the summary.

Seung Kim, MD, MSa ∙ Netali Ben-Baruch Morgenstern, PhDa ∙ Kasumi Osonoi, MDa ∙ Seema S. Aceves, MD, PhDb ∙ Nicoleta C. Arva, MD, PhDc ∙ Mirna Chehade, MD, MPHd ∙ Margaret H. Collins, MDe ∙ Evan S. Dellon, MD, MPHf ∙ Gary W. Falk, MD, MSg ∙ Glenn T. Furuta, MDh ∙ Nirmala P. Gonsalves, MDi ∙ Sandeep K. Gupta, MDj ∙ Ikuo Hirano, MDi ∙ Girish Hiremath, MD, MPHk ∙ David A. Katzka, MDl ∙ Paneez Khoury, MD, MHSm ∙ John Leung, MDn ∙ Robbie Pesek, MDo ∙ Kathryn A. Peterson, MD, MScip ∙ Maria A. Pletneva, MD, PhDq ∙ Jonathan M. Spergel, MD, PhDr ∙ Joshua B. Wechsler, MD, MSs ∙ Guang-Yu Yang, MD, PhDt ∙ Marc E. Rothenberg, MD, PhDa ∙ Tetsuo Shoda, MD, PhD. Nonepithelial Gene Expression Correlates With Symptom Severity in Adults With Eosinophilic Esophagitis. The Journal of Allergy and Clinical Immunology: In Practice, Volume 12, Issue 12, 3346 - 3355.e1. how the immune system is recognizing food antigens

This blog post is a research roundup of recent publications on eosinophilic diseases, including summaries, links, and citations for the following articles:

Longer-Term Biologic Use to Treat Severe Asthma/Eosinophilic Asthma

Doctors studied how well biologics work for people with severe asthma. They looked at 611 patients who used these medicines for at least a year. Almost half of the patients (46%) had their asthma get much better at some point during the study. This means they didn’t have any bad asthma attacks, didn’t need strong steroid medicines, and felt their breathing was under control. The longer patients used the biologics, the more likely they were to feel better. After 4 years of treatment, about 1 in 3 patients had their asthma well controlled.

On-treatment clinical remission of severe asthma with real-world longer-term biologic use. Chipps, Bradley E. et al. Journal of Allergy and Clinical Immunology: Global, Volume 4, Issue 1, 100365

Does Esophageal Dilation Impact Efficacy of Budesonide to Treat EoE?
Researchers studied how well budesonide oral suspension (BOS) works for people with EoE. Some patients with EoE have had esophageal dilation (stretching their esophagus to improve swallowing). The study looked at how BOS worked for those who had a previous esophageal dilation compared to those who have not had a dilation. They found that BOS helped reduce inflammation in the esophagus for both groups. However, people who had their esophagus stretched before didn’t feel as much improvement in swallowing as those who never had it stretched. This study helps doctors understand that a patient’s history of esophagus stretching might affect how they respond to this new medicine for EoE.

Hirano, Ikuo MD (posthumous)1; Collins, Margaret H. MD2; Katzka, David A. MD, FACG3; Mukkada, Vincent A. MD4; Falk, Gary W. MD, MS5; Terreri, Brian PharmD, MBA6; Boules, Mena MD6; Zhang, Wenwen PhD7; Desai, Nirav K. MD7; Dellon, Evan S. MD, MPH, FACG8. Effect of Esophageal Dilation History on Efficacy Outcomes in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral Suspension. The American Journal of Gastroenterology ():10.14309/ajg.0000000000003197, November 12, 2024. | DOI: 10.14309/ajg.0000000000003197

Understanding Fibroblasts and Their Impact on the Esophagus
Researchers studied how EoE affects special cells called fibroblasts. These cells help heal and repair tissues. The study found that fibroblasts in people with EoE behave differently than normal. They tend to make the esophagus more rigid, similar to cartilage tissue. Instead of creating soft, flexible cells, these fibroblasts become more stiff and structured. They also move around more aggressively within the esophagus. Another key finding was that these cells have less of a specific protein on their surface, which disrupts their normal healing process. These changes make it harder for the esophagus to heal properly. The researchers discovered that adding a substance called adenosine could help fix some of these problematic cell behaviors. This study helps doctors understand why EoE causes long-term damage to the esophagus and suggests new ways to treat it.

Eosinophilic esophagitis drives tissue fibroblast regenerative programs toward pathologic dysfunction. Jumabay, Medet et al. Journal of Allergy and Clinical Immunology, Articles in Press

Men Face More Challenges with EoE: New Study Reveals Gender Differences

Researchers studied how eosinophilic esophagitis (EoE), a condition that causes inflammation in the esophagus, affects men and women differently. They looked at hospital records of nearly 22,000 patients with EoE from 2016 to 2020.The study found that men with EoE have more problems than women. Men were more likely to have their esophagus blocked, get food stuck, or have their esophagus tear. This was especially true for men aged 25-29. Women with EoE had fewer complications, but those aged 75-79 were more likely to have food get stuck. Interestingly, more black women had EoE compared to black men, but black men still had more complications. The researchers also noticed that men were most likely to have serious problems with their esophagus in March. This study helps doctors understand that EoE affects men and women differently, which could lead to better ways of treating patients based on their gender and age.

Patel H, Elmer J, Liaquat H. Exploring the impact of gender on the characteristics and complications of eosinophilic esophagitis. JGH Open. 2024;8(12):e70059. doi:10.1002/jgh3.70059